#Adenovirus Vector Vaccine Market Forecast

[lalsingh228-blog]

Adenovirus Vector Vaccine Market Projected to Show Strong Growth

The Latest research coverage on Adenovirus Vector Vaccine Market provides a detailed overview and accurate market size. The study is designed considering current and historical trends, market development and business strategies taken up by leaders and new industry players entering the market. Furthermore, study includes an in-depth analysis of global and regional markets along with country level market size breakdown to identify potential gaps and opportunities to better investigate market status, development activity, value and growth patterns. Access Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/165891-global-adenovirus-vector-vaccine-market

Major & Emerging Players in Adenovirus Vector Vaccine Market:- Creative Biolabs (United States), Sartorius AG (Germany), Lonza (Switzerland), Merck KGaA (Germany), Cobra Biologics (United States), Thermo Fisher Scientific (United States), Boehringer Ingelheim (Germany), Oxford Biomedica (United Kingdom), Advanced Bioscience Laboratories (United States). The Adenovirus Vector Vaccine Market Study by AMA Research gives an essential tool and source to Industry stakeholders to figure out the market and other fundamental technicalities, covering growth, opportunities, competitive scenarios, and key trends in the Adenovirus Vector Vaccine market. Adenovirus represents the class of the genetically diverse DNA viruses that can cause non-life-threatening infections related to eyes, respiratory system, gastrointestinal lining and other parts. These viruses represent promising results as a vector for delivering target antigens to various hosts due to excellent ability induce immune response. Due to these property, the new studies concluded positive results for use of adenovirus for both gene therapy and vaccine production. Adenovirus-based vectors shows various benefits when compared to other viral vectors such as wide range of tissue tropism, ease of genetic manipulation especially for large transgene DNA insertions, superior ability to induce robust transgene-specific T cell and antibody responses, easy production of the adenovirus based vaccines at large scale. Due to this, it has emerged as a preferred choice for delivering vaccine for both humans as well as animals.

In February 2021, the Janssen Biotech, a part of Johnson and Johnson submitted Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA), for its investigational single-dose coronavirus 2019 (COVID-19) vaccine candidate. The vaccine Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein

In January 2021, Thermo Fisher Scientific, a company offering range of instrumentation, reagents and consumables, and software and services acquired the viral-vector manufacturing business of the Novasep, a pharmaceutical company for approximately USD 875 million in cash. This acquisition is a step towards expanding Thermo Fisher capabilities in the cell and gene vaccines and therapies worldwide. The titled segments and sub-section of the market are illuminated below: by Type (Adenovirus-based tuberculosis vaccine, Adenovirus-based HIV vaccine, Adenovirus-based influenza vaccine, Others), Application (Human, Animals), End-user (Hospitals, Ambulatory Surgical Center, Research Institutes, Others) Market Trends: Increasing investment in vaccine and drug development

Rising collaboration between the pharmaceutical companies and CROs for development of adenovirus vector vaccine

Opportunities: Emergence of adenovirus vectored vaccines for COVID-19      

Production of low cost adenovirus vaccines

Market Drivers: Growing prevalence of chronic medical conditions

Rise in demand for efficient vaccines to treat infectious diseases Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/165891-global-adenovirus-vector-vaccine-market Some Point of Table of Content: Chapter One: Report Overview Chapter Two: Global Market Growth Trends Chapter Three: Value Chain of Adenovirus Vector Vaccine Market Chapter Four: Players Profiles Chapter Five: Global Adenovirus Vector Vaccine Market Analysis by Regions Chapter Six: North America Adenovirus Vector Vaccine Market Analysis by Countries Chapter Seven: Europe Adenovirus Vector Vaccine Market Analysis by Countries Chapter Eight: Asia-Pacific Adenovirus Vector Vaccine Market Analysis by Countries Chapter Nine: Middle East and Africa Adenovirus Vector Vaccine Market Analysis by Countries Chapter Ten: South America Adenovirus Vector Vaccine Market Analysis by Countries Chapter Eleven: Global Adenovirus Vector Vaccine Market Segment by Types Chapter Twelve: Global Adenovirus Vector Vaccine Market Segment by Applications What are the market factors that are explained in the Adenovirus Vector Vaccine Market report?

– Key Strategic Developments: Strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors.

– Key Market Features: Including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin.– Analytical Tools: The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market. Buy This Exclusive Research Here: https://www.advancemarketanalytics.com/buy-now?format=1&report=165891 Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market. Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[prajwal-agale001]

Viral Vaccines Growth Drivers: Technological Advancements and Emerging Markets

The viral vaccines market is on track for notable expansion, with forecasts indicating it will reach $47.01 billion by 2031, achieving a compound annual growth rate (CAGR) of 1.9% from 2024 to 2031, according to the latest report from Meticulous Research®. This growth is fueled by a robust product pipeline, increased government emphasis on immunization programs, technological advancements in vaccine administration, and the capacity expansion of biopharmaceutical products.

Key Drivers of Market Growth

Several factors are driving the upward trajectory of the viral vaccines market:

Strong Product Pipeline: The ongoing development and approval of new vaccines are boosting market growth. Innovative vaccine formulations and delivery methods are continually advancing, making vaccines more effective and easier to administer.

Government Focus on Immunization: Governments worldwide are increasingly prioritizing immunization programs to combat infectious diseases and improve public health. This focus is translating into expanded vaccine distribution and coverage.

Technological Advancements: Advances in vaccine administration technologies, including ultra-low temperature freezers that ensure vaccine stability, are facilitating better vaccine storage and handling. Additionally, the use of inactivated vaccines in surgical treatments is contributing to market expansion.

Emerging Markets and Therapeutic Vaccines: The growing emphasis on therapeutic vaccines, which target diseases beyond traditional infections, is opening new avenues for market growth. Emerging markets are also becoming significant contributors due to increased healthcare investments and expanding vaccination programs.

Market Segmentation and Insights

The viral vaccines market is segmented into several categories, each influencing the market dynamics in unique ways:

Form

Liquid Vaccines: In 2024, liquid vaccines are expected to dominate the market. These vaccines, which are easy to administer and do not require reconstitution, offer advantages such as reduced risk of errors, simplified logistics, and lower contamination risks. Their widespread use is driven by the need for efficient vaccination processes.

Lyophilized Vaccines: While liquid vaccines are currently leading, lyophilized vaccines also play a crucial role. They require reconstitution before use but offer longer shelf lives and stability, which are essential for certain types of vaccines.

Vaccine Type

Subunit & Conjugate Vaccines: Expected to hold the largest market share in 2024, this segment includes vaccines that do not contain live components. These vaccines are valued for their precise targeting of pathogens, low risk of immunogenicity, and long-term immunity.

Other Vaccine Types: Live-attenuated, inactivated, mRNA, viral vector, toxoid, and combination vaccines each contribute to the market's growth. Each type offers specific benefits, such as enhanced immune responses or targeted disease prevention.

Virus Type

Adenovirus: The adenovirus segment is anticipated to lead the market due to its efficient gene delivery, strong immune response, and high scalability. Adenovirus vectors are widely used in vaccine development and gene therapy.

Other Virus Types: Retrovirus, plasmid DNA, adeno-associated virus (AAV), and lentivirus are also significant, each with unique properties that support various vaccine and therapeutic applications.

Route of Administration

Intramuscular (IM) and Subcutaneous (SC): These routes are commonly used for most vaccines due to their effectiveness in eliciting immune responses.

Oral and Other Routes: Alternative administration methods, such as oral vaccines, are gaining attention for their ease of use and potential for mass immunization.

Approach

Preventive Vaccines: Preventive vaccines are expected to dominate the market. These vaccines are administered to prevent infections and are integral to public health strategies aimed at controlling infectious diseases.

Therapeutic Vaccines: Therapeutic vaccines, which target diseases such as cancer, are emerging as important growth areas, offering new treatment possibilities and expanding the scope of vaccination beyond disease prevention.

Indication

Infectious Diseases: This segment is projected to hold the largest share due to the high demand for vaccines that prevent and control infectious diseases. The prevention of diseases, reduction in morbidity and mortality, and global health security drive this market segment.

Other Indications: Vaccines for cancer, genetic disorders, and other indications are also important, with ongoing research and development contributing to their growth.

Application

Antisense Therapy: Expected to capture the largest market share in 2024, antisense therapy uses viral vectors to induce immune responses. This approach offers comprehensive protection against a range of pathogens and is supported by advancements in technology and increased healthcare spending.

Other Applications: Gene therapy, cell therapy, and vaccinology also contribute to market growth, with applications tailored to specific therapeutic needs.

Packaging

Vials and Prefilled Syringes: Packaging plays a crucial role in vaccine distribution and administration. Vials and prefilled syringes are commonly used to ensure accurate dosing and ease of use.

Regional Insights

The global viral vaccines market is influenced by regional dynamics:

North America: Projected to hold the largest market share in 2024, North America benefits from advanced research infrastructure, a high concentration of pharmaceutical companies, and significant investments in vaccine development. The region's focus on immunization and preparedness for emerging pandemics further supports its leading position.

Emerging Markets: Regions such as Asia-Pacific are experiencing rapid growth due to industrial expansion, increased healthcare investments, and improved vaccination programs. Countries like China, India, and Japan are driving this growth through enhanced public health initiatives and expanding vaccine accessibility.

Recent Developments

The viral vaccines market has seen significant recent developments, including collaborations and innovations. For instance, in January 2024, a notable collaboration between ReiThera Srl, the Ragon Institute of Mass General, MIT, Harvard, and the International AIDS Vaccine Initiative (IAVI) was announced. This partnership aims to develop a novel HIV vaccine candidate using ReiThera’s GRAd vector, marking a significant advancement in vaccine research.

Additionally, in October 2023, the R21/Matrix-M malaria vaccine developed by Oxford University and the Serum Institute of India, utilizing Novartis AG’s adjuvant technology, received recommendations from the WHO’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). This development highlights ongoing efforts to combat infectious diseases through innovative vaccine technologies.

Read Full Report @ https://www.meticulousresearch.com/product/viral-vaccines-market-5920

Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research

[pharmanucleus1]

Viral Vector Gene Delivery Market: Advancements, Opportunities, and Future Trends

Market Overview 

Viral vector is the most sought-after way to transfer genes to specific cell types or tissues and manipulate them to express therapeutic genes. Currently, there are several types of viruses, such as adenovirus, adeno associated virus, baculovirus and retrovirus, which are being investigated in order to deliver the genes to required cells. This process can provide permanent as well as transient transgene expression.

Market Dynamics 

Viral vectors are primarily used in the development of various gene therapies and are showing great promise in disease landscape. Moreover, during the unprecedented times of COVID-19, the development of adenovirus-vector vaccine has helped to mitigate the dangerous risks associated with the pandemic.? 

Since the viral vector-based gene therapies have shown promising results in the past, the developers are exploring its full potential to reach to its long-term success. With the ongoing rise in demand, the service providers are continuously expanding their facilities to meet the numbers. In August 2022, Thermofischer has expanded its cell and gene therapy capability by opening the new viral vector manufacturing facility in Massachusetts, US. 

In June 2022, VIVEbiotech has completed the acquisition of its lentiviral vector manufacturing capabilities to support the customers throughout the development cycle. 

In June 2022, Avid Bioservices expanded its viral vector focused facility with 53,000 sq. ft. area to address the demand of viral vector production at commercial scale. 

The increasing prevalence of various genetic disorders and target diseases increased funding availability for development of gene therapy, research efforts in the field of viral vector-based cell and gene therapies, and increasing efficacy of viral vectors in delivering gene therapy are fueling growth in the global viral vectors manufacturing market. 

Click here for full report:

Challenges 

The ongoing challenge, which is linked with its ability to pass the immune system and high number of doses are some of the limiting factors delaying the success of such therapies. Further, the quality of transgene expression plays another crucial role for the desired clinical effect. The combinatorial factors demand innovations at the R&D scale, which will gain traction in investment from various organizations. 

In June 2022, NSW Government of Australia allocated USD 101.4 million to the commercial facility of viral vector manufacturing. This clearly indicates the need to improve the viral vector-based therapy due to its significant potential to cure multiple indications.?? 

Development Landscape: 

Biotech and pharmaceutical businesses are adopting both organic and inorganic growth strategies to advance their pipeline and gain competitive edge in the market over the peers. 

In April 2022, ProteoNic and NecstGen announced a collaboration, wherein the respective players will utilize their proprietary platforms to advance the AAV and LV viral vector manufacturing technology. 

Till now, only eight viral vector-based gene therapies have been approved by the US FDA, which were developed using three viral vectors- adeno associated virus, lentivirus and herpes simplex virus. 

As of September 2022, over 145 clinical trial studies are going on with over 10,000 patients worldwide. The exploratory pipeline of viral vector-based therapy continues to grow across the indications and targets with promising results. 

Click here for free sample report:

Key players: 

Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US) 

Click here for full report:

https://www.pharmanucleus.com/reports/viral-vector-gene-delivery

Upcoming players: 

TBD 

Regional Analysis: 

North America?is anticipated to capture the highest share of this market over the forecast period (2022-2027), with U.S. accounting for the maximum contribution. Presence of most number of manufacturing facilities and key players, some of the best research universities and an encouraging start-up eco system provides an ideal environment for research leading to more successful assets in pipeline. Macro-economic factors such as large population and growing economy, high prevalence of cancer and infectious diseases, better access to insurance, availability of crowd funding and support from various stakeholders’ fuels US as a commercially attractible market. 

In 2019, the New Jersey Innovation Institute signed an agreement with Pall Corporation to develop a BioPharmaceutical Innovation iLab to help fix the viral vector shortage using continuous manufacturing. 

Thermo Fisher Scientific opened a cGMP manufacturing facility in Plainville, US which helped double the company’s commercial viral vector capacity?and?meet rising demand for the development and manufacturing of gene therapies and vaccines. 

Europe?also remains a favourable region on par with the North American region. Presence of highly skilled researchers, well-developed R&D ecosystem, support from government agencies and regulatory bodies are the major driving factors in Europe. 

In 2021, Yposkesi announced that its bioproduction project has been selected for the French government’s “Plan de Relance” initiative, which is an economic stimulus package aimed at making the nation’s bioproduction industry strategically more robust and economically resilient is investing USD6 million in its “Boost” project to develop a new generation 1000-L, GMP platform with optimized manufacturing and control processes for efficient viral vector production from the thawing of cells up to the aseptic filling of the end product. 

Asia-Pacific?region is expected to pick up pace over the next few years due to favourable regulatory climate, increasing investments to drive market access in key markets such as Japan, China, Australia, Singapore and India. The market is focusing on Asia-Pacific as a destination for outsourcing and trying to gain foothold through mergers, collaborations, and strategic acquisitions. 

In 2022, National Cancer Center Japan and GenScript ProBio entered into research collaboration agreement for a plasmid and lentiviral vector CMC development to develop plasmid and lentiviral vector for cell therapy to aim on FDA acceptance of IND applications. 

In 2022, VectorBuilder, a CDMO announced an investment of USD 500m for China viral vector plant. The campus will include 30 production suites designed to manufacture lentivirus, plasmids, messenger RNA (mRNA), adeno-associated virus (AAV), cell lines and other types of viral and non-viral vectors. 

[esglatestmarketnews]

Viral Vector—Perusal on Adeno-associated Viruses (AAVs) in Gene Therapy Development

The medical industry expects viral vectors to grow in prominence in transferring genetic material into the genetic composition of cells. Adeno-associated Viruses (AAVs) have become sought-after in gene therapy as they can deliver genetic material to cells and do not cause disease. Predominantly, adenovirus, retrovirus, herpes simplex virus and lentivirus, among others, are used to transfer genetic material into cells’ genetic composition. Technological advancements in manufacturing AAV vectors have encouraged stakeholders to boost their portfolios. An uptick in research activities in viral vector-based cell and gene therapies has redefined the global landscape. For instance, in 2020, over 100 gene-therapy products were observed in clinical trials.

Pharma companies, investors, venture capitalists and other stakeholders will possibly explore the growth potential in viral vectors. The final report, along with the database, will deep-dive into the following industry dynamics:

• AAV vectors approved by governing bodies, including FDA and the European Medicines Agency. Zolgensma was approved by EMA and FDA in 2020 and 2019, respectively, while Luxturna received the green signal from FDA in 2017 and EMA in 2018. 

• Insights on potential challenges for AAV manufacturers, such as cost, degradation during supply chain and preparation of stable viral vectors.

• Influence of the COVID-19 pandemic on vaccine development.

• Acquisitions of biotech startups

Get your copy or request a free sample of the report “Viral Vector Development - Focus on Adeno-associated Virus, 2018 – 2021,” compiled and published by Grand View Research.

Viral Vector Report Scope

Attribute

Details

Market Lineage

% Captured by AAV within Viral Vectors

Understanding of the parent market and ancillary industries

Plasmid DNA Contract Manufacturing

Cell & Gene Therapy Clinical Trials Market

Industry Dynamics

Viral Vector based gene therapy development

AAV Development workflow

Pipeline for AAV

Capitalist funding in the industry

Development Process

Deep dive Analysis

Understanding of AAV v/s Lentiviral v/s other viral vectors

Cost of manufacturing (based on batch size) - a case study

Case study on setting up a development plant

Competition Analysis in CDMOs

Companies with products in clinical trials

Various bioreactors used for development

Strategic initiatives undertaken in the last 5 years

Observation and Recommendations

This section will summarize the entire study and provide analyst insights with regards to key methods of development, technological advancements, and competitive profiling

Get more insights from our in-depth market intelligence report “Viral Vector Market Size, Share & Trends Analysis Report By Vector Type (Adeno-associated Virus (AAV), Adenovirus, Lentivirus, Retrovirus, Others), By Application, By End-user, By Region, And Segment Forecasts, 2023 – 2030”

About Us

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.

Find More information @ https://www.grandviewresearch.com/info/trend-reports

[balrajgis]

Viral Vectors And Plasmid DNA Manufacturing Market overview by recent opportunities, growth size, regional analysis and forecasts to 2031 | Genelux Corporation, Kaneka Eurogentec S.A., Lonza Group AG

Global Viral Vectors And Plasmid DNA Manufacturing Market report from Global Insight Services is the single authoritative source of intelligence on Viral Vectors And Plasmid DNA Manufacturing Market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters’ and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types, applications, and geographies. Report also includes comprehensive analysis of key issues, trends and drivers, restraints and challenges, competitive landscape, as well as recent events such as M&A activities in the market.

A viral vector is a virus that has been genetically modified to carry a foreign gene into a cell. The foreign gene may encode a protein that confers a new property to the cell, such as resistance to a particular drug. Alternatively, the foreign gene may be a piece of DNA that the researcher wishes to insert into the cell’s genome.

Get Free Sample Copy of This Report – https://www.globalinsightservices.com/request-sample/GIS21443/

Key Trends

The key trends in viral vectors and plasmid DNA manufacturing technology are:

1. Increasing use of viral vectors and plasmid DNA for gene therapy and vaccine development

2. Improvements in vector design and manufacturing processes

4. Decreasing costs of viral vectors and plasmid DNA

Key Drivers

There are several key drivers of the Viral Vectors and Plasmid DNA Manufacturing market. One of the most important drivers is the increasing demand for gene and cell therapies. Gene therapies are becoming more prevalent as treatments for a variety of conditions, including cancer, genetic disorders, and infectious diseases. In addition, cell therapies are being developed for a variety of applications, including regenerative medicine and immunotherapy.

Key Segments

By Vector Type

Adenovirus

Retrovirus

By Workflow

Upstream Manufacturing

Downstream Manufacturing

By Application

Gene Therapy

Cell Therapy

By End-Use

Pharmaceutical & Biopharmaceutical Companies

Research Institutes

By Region

North AmericaThe U.S.

Request For Customization – https://www.globalinsightservices.com/request-customization/GIS21443

Key Players

Genelux Corporation

Kaneka Eurogentec S.A.

Lonza Group AG

MaxCyte, Inc.

Merck KGaA

Novasep Inc.

Vector Biolabs

Vigene Biosciences, Inc.

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Excel data pack included with all report purchases

Robust and transparent research methodology

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1–833–761–1700

[metiresearchinfo]

Pharmaceutical Contract Development and Manufacturing Market By Service [Pharmaceutical Manufacturing Services (API, FDF), Drug Development Services, Biologics Development], End User [Big & Generic Pharmaceutical Companies] – Global Forecast to 2027

The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 6.5% from 2020 to 2027 to reach $134.23 billion by 2027. The complex structure for manufacturing pharmaceuticals, increasing investments in pharmaceutical R&D, growing outsourcing of clinical trials, and the outbreak of the COVID-19 pandemic are some of the major drivers for the growth of this market. In addition, the rising demand for generic medicines & biologics, growing demand for cell & gene therapies, and increasing pharmaceutical outsourcing support the growth of this market. However, service quality & IPR issues, lack of skilled professionals, and introduction of serialization are the factors expected to hinder the growth of the pharmaceutical contract development and manufacturing market during the forecast period.  

COVID-19 Impact on the Pharmaceutical Contract Development and Manufacturing Market      

The recent outbreak of COVID-19 has impacted the healthcare market. The pharmaceutical contract development and manufacturing industry has experienced a positive impact due to this pandemic. The outbreak has catalyzed the demand for pharmaceuticals and has stirred the development of corona-related vaccines, antiviral vaccines, antibody therapy, and various pharmaceutical products. This has urged pharmaceutical organizations to hire contract development and manufacturing organizations for pharmaceutical drug development & manufacturing to sustain their business.

The demand for both high quality and high volume CGMP drug substance and drug product manufacturing services has soared, particularly for CDMOs able to support a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

Most pharmaceutical companies, CROs, and research institutes are working together to translate research into effective pharmaceutical products. For instance, in August 2020, Catalent Inc. (U.S.) signed an agreement with AstraZeneca PLC (U.K.) to expand manufacturing support for the University of Oxford’s adenovirus vector-based COVID-19 vaccine AZD1222. In September 2020, Thermo Fisher Scientific Inc. (U.S.) partnered with Inovio Pharmaceuticals, Inc. (U.S.) to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800 and to enhance the commercial production of INO-4800.

                                                              Click here to: Get Free Sample Pages of this Report

Increasing investments in the pharmaceutical R&D support the market growth

The pharmaceutical industry is largely driven by scientific discovery and development, in conjunction with toxicological and clinical experience. Also, healthcare R&D activities have significantly increased with rising funding from various government organizations. This funding is mainly driven by rising health care concerns, complexities in clinical trials, and drug failure in early-phase studies.

Governments in developed and developing nations are offering to fund the propagation of biotechnology and biopharmaceutical research. For instance, the Indian government launched 'Pharma Vision 2020' to increase the production capacities of biopharmaceuticals by reducing the approval time for new facilities. Also, the government decided in favor of 100% foreign direct investment in the pharmaceutical industry, which is expected to increase investments in R&D activities. Similarly, in the U.S., the National Institute of Health (NIH) collaborated with 11 biopharmaceutical companies to launch the Partnership for Accelerating Cancer Therapies (PACT) to develop immunotherapy for cancers. The program involved a total investment of USD 215 million.

Further, pharmaceutical companies have also increased their spending on R&D. The extent of pharmaceutical R&D spending serves as an important metric to show a company’s commitment to finding new drugs. At present, the global pharmaceutical industry has the second-highest R&D intensity, i.e. expenditure as a share of any sector's sales measures. Thus, the increasing investments from the government for pharmaceutical R&D is likely to boost outsourcing, thereby accelerating pharmaceutical contract development & manufacturing market growth.

Growing consolidation in the market, an ongoing trend

Due to growing pressure on leading pharmaceutical players, complex drug development process, growing number of patents expiring, increasing R&D costs, and the increasing prevalence of chronic diseases are some of the factors making outsourcing essential.

CDMOs offer the convenience of time and cost due to the inherent nature of dealing with a single entity. The relationship also creates opportunities for the pharmaceutical CDMOs to sell more services to the same customer and locking in products at earlier stages of their life cycles.

Due to the growing pressure on the industry’s leading players to follow stringent regulatory timelines and lack of human clinical trial data, pharmaceutical giants are entering into collaborations, partnerships, and agreements to jointly broaden their services offered across all drug development & pharmaceutical manufacturing processes:

In June 2020, Catalent Inc. (U.S.) collaborated with Moderna, Inc. (U.S.) for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273).

In April 2020, ICON plc (Ireland) agreed with Pfizer Inc. (U.S.) to supply drug and device development and commercialization services.

                                              Click here to: Get a Free Request Sample Copy of this report

Key Findings in the Pharmaceutical Contract Development and Manufacturing Market Study:

Pharmaceutical manufacturing services generated a large proportion of revenue compared to other services

The large share of this segment is mainly attributed to the use of advanced technologies & manufacturing skills, the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs.

Pharmaceutical API contract manufacturing services are estimated to account for the largest share of the pharmaceutical contract manufacturing services market in 2020

The need for the reduction in the cost of production of APIs, growing number of initiatives undertaken by pharmaceutical companies, increasing investments in API manufacturing services, and growing need to reduce the time required for the drug development process are expected to drive the growth of the pharmaceutical API contract manufacturing services segment.

In 2020, the big pharmaceutical companies segment to dominate pharmaceutical contract development and manufacturing market

The major share of this segment is primarily attributed to the growing prevalence of various infectious diseases, growing need for state-of-the-art processes & production technologies, and the rising cost of clinical trials and early development studies.

Asia-Pacific: Fastest growing regional market

In 2020, North America is estimated to command the largest share of the pharmaceutical contract development and manufacturing market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific will be the fastest-growing regional market due to the growing manufacturing sector, favorable government regulations, increasing emphasis on off-patent drugs, and highly skilled workforce in the region. In addition, the increase in outsourcing activities in countries like India and China due to lower costs and availability of qualified healthcare professionals are the other key factors propelling the growth of the Asia-Pacific pharmaceutical contract development and manufacturing market.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past four years. The key players profiled in the pharmaceutical contract development and manufacturing market report are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.),  PPD Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma-Fertigung GmbH & Co. KG  (Germany), AbbVie Inc. (U.S.), Synoes Health, Inc. (U.S.), Piramal Enterprises Limited (India), Almac Group (U.K.), Albany Molecular Research Inc. (U.S.), Fareva Holding SA (France), and Jubilant Life Sciences Limited (India).

Scope of the Report:

Pharmaceutical Contract Development and Manufacturing Market, by Service

Pharmaceutical Manufacturing Services

Drug Development Services

Biologics Manufacturing Services

Pharmaceutical API Manufacturing Services

Pharmaceutical FDF Manufacturing Services

Parenteral/Injectable Manufacturing Services

Tablet Manufacturing Services

Capsule Manufacturing Services

Oral Liquid Manufacturing Services

Other Formulations Manufacturing Services

Biologics API Manufacturing Services

Biologics API Manufacturing Services

Pharmaceutical Contract Development and Manufacturing Market, by End User

Big Pharmaceutical Companies

Small and Med-Size Pharmaceutical Companies

Generic Pharmaceutical Companies

Pharmaceutical Contract Development and Manufacturing Market, by Geography

North America

Europe

Asia-Pacific (APAC)

Latin America

Middle East & Africa

U.S.

Canada

Germany

U.K.

France

Italy

Spain

Rest of Europe (RoE)

China

Japan

India

Rest of APAC (RoAPAC)

[vicky8588]

Viral Vector and Plasmid DNA Manufacturing Market

Market Overview

The Global "Viral Vector and Plasmid DNA Manufacturing Market" are expected to grow at a high CAGR of 18.8% during the forecasting period (2021-2028).

 The viral vector is referred to as the tool for delivering genetic material into cells. The modified viral vector is used as viral vectors in gene therapy. Plasmid DNA is a bacterial smaller, circular, and extrachromosomal DNA used in different molecular genetic research such as gene therapy, gene transfer, and recombinant DNA technology due to its self-replication property. A gene of interest is transferred into the target cell for studying the function or expression of a gene.

Get Free Sample : https://www.datamintelligence.com/download-sample/viral-vector-and-plasmid-dna-manufacturing-market

Market Dynamics:

The market is driven by the increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others. There are growing viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is an increase in the number of clinical studies examining the viral vectors' efficacy and safety and plasmid DNA.

 There is an increase in the contract manufacturing business launch for viral vectors and plasmid DNA manufacturing. For instance, in December 2019, Helixmith Co., Ltd. and Genopis had launched the contract manufacturing business for plasmid DNA production. The company would establish additional smaller-scale reactors (60-300 L, 6-30 L) with feasibility runs and start a small-volume production service. Genopis is equipped with the right technologies and quality systems.

 Several companies are entering into a collaboration with several organizations to manufacture viral vectors and plasmid DNA. For instance, in June 2020, Oxford Biomedica plc had entered into a collaboration agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization established to provide the UK’s first strategic vaccine development and advanced manufacturing capability. This five-year agreement would involve the organizations working collaboratively to enable the manufacture of viral vector-based vaccines, contributing to a rapid increase in the United Kingdom domestic capacity for this specialized vaccine manufacturing field. Under the terms of the agreement, VMIC would provide manufacturing equipment for Oxford Biomedica to equip two new GMP manufacturing suites within Oxford Biomedica’s new 7,800 m2 commercial manufacturing center, Oxbox, located in Oxford, United Kingdom.

  Segment Analysis

The global viral vector and plasmid DNA manufacturing market is segmented on the product type as the plasmid DNA, viral vector, and non-viral vector. The viral vector segment accounts for the highest market growth due to the increasing penetration of the viral vectors for targeted delivery, efficient transduction, and controlled gene expression. There is an increase in the viral vectors' usage due to their efficiency in delivering genes into the target cells and protecting the new genes from degradation. Different types of viral vectors such as retrovirus, lentivirus, adenovirus, adeno-associated virus, and herpes simplex virus are used for transferring the nucleic acids into the genetic makeup of cells. Out of these viral vectors, adenovirus and retrovirus are widely used worldwide as these viral vectors have the integration ability with large transgenes and easy production at high titers.

 Several companies are focusing on expanding the manufacturing facilities for the viral vectors to meet the increasing demand. For instance, in May 2019, Thermo Fisher Scientific Inc. had opened its new $90 million viral vector contract development and manufacturing organization (CDMO) site in Lexington, MA. The 50,000-square-foot facility would support the development, testing, and manufacture of viral vectors essential for advancing gene and cell therapies globally.

   Further, the market is also classified based on cancer, genetic disorder, infectious disease, and other diseases. The cancer segment accounts for the highest market share of XX% in 2019 due to the higher usage of the viral vector and plasmid DNA for delivering the anti-cancer genes. Several biotechnology and pharmaceutical companies are examining the viral vectors or plasmid DNA encoding a therapeutic gene, often an immunomodulatory or suicide gene, in the various cancer gene therapy trials. Clinical studies have demonstrated that the injection of a plasmid DNA encoding a cytokine gene has a significant antitumor effect. There is increasing research and development activities for gene therapies and other advanced cell therapies to treat various cancers. The increase in the approval of the viral vector and plasmid DNA-based therapies shall stimulate market growth. For instance, the lentiviral vector-based CAR-T cell therapies' approval for treating Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma.

 Geographical Presentation

By region, the global viral vector and plasmid DNA manufacturing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global viral vector and plasmid DNA manufacturing market and is expected to grow at the highest CAGR during the forecasted period due to the increasing number of clinical studies for evaluating the use of the viral vector and plasmid DNA for the treatment of the genetic disorders, cancer, and infectious diseases. The increase in the approval of advanced cell therapies shall stimulate market growth. There is growing research and development activities of gene therapies. Several companies, institutes, associations, and foundations raise the investment and funding to develop gene therapies. The growing initiatives by the Food and Drug Administration (FDA) for improving the regulatory support for cell and gene therapy shall boost the demand for viral vector and plasmid DNA manufacturing.

 The Asia Pacific is expected to witness positive market growth due to the growing clinical transformation and industrialization of advanced therapies medicinal products, including gene therapy manufacturing. There is a presence of several companies manufacturing the viral vector and plasmid DNA. Contract manufacturers are providing several services for viral vector and plasmid DNA manufacturing. There is growing adoption of advanced technologies for manufacturing viral vectors and plasmid DNA.

 View Full Report : https://www.datamintelligence.com/research-report/viral-vector-and-plasmid-dna-manufacturing-market#

 Competitive Analysis

The global viral vector and plasmid DNA manufacturing market are highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., Thermo Fisher Scientific, and Uniqure NV are the leading market players with significant market share.

 The major players enter into collaborations, acquisitions, mergers, and licensing activities to increase their market presence. For instance, in August 2019, FUJIFILM Corporation had acquired the Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark, from Biogen. The Hillerød Manufacturing site would be the fourth biopharmaceutical manufacturing site of FUJIFILM Diosynth Biotechnologies, a Fujifilm subsidiary, and a leading Contract Development and Manufacturing Organization (CDMO) with expertise in the development and manufacture of biologics and advanced therapies.

 In March 2019, Merck had entered into the non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on a plasmid and viral vector manufacturing. The manufacturing of high-quality plasmids and viral vectors would help in the commercialization of cell and gene therapy. This collaboration would help the company accelerate the industrialization and commercialization of cell and gene therapy in China. Merck would provide GenScript with comprehensive products, training, consulting services covering process design, facility concept design, and quality management system set-up from lab development to large-scale GMP manufacturing.

 In December 2017, MilliporeSigma had entered into the commercial supply agreement to manufacture viral vectors for bluebird bio, Inc., of Cambridge, Massachusetts, for its use in potentially transformative gene therapies. MilliporeSigma would manufacture lentiviral vectors for bluebird bio's drug products developed to treat various rare genetic diseases under the agreement's terms. This contract builds upon MilliporeSigma's deep experience producing viral vectors for gene therapy from clinical to commercial scale.

 In June 2014, Applied Genetic Technologies Corporation had entered into the collaboration with the Sigma-Aldrich Corporation to provide gene therapy manufacturing services to companies developing gene-based therapies. Under the terms of the agreement, the two companies will co-market AGTC's proprietary HAVE manufacturing method with SAFC's cGMP manufacturing capabilities. AGTC will assist clients in engineering AAV-based vectors and the associated helper viruses for HAVE-based manufacturing activities. SAFC will manufacture AAV vectors with the HAVE system to either support initial research or by cGMP requirements to support clinical trial development and eventual commercial production.

 Enquiry Before Buying : https://www.datamintelligence.com/enquiry/viral-vector-and-plasmid-dna-manufacturing-market

 About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

 For more information:

Sai Kiran

Sales Manager at Data M Intelligence

Email: info@datamintelligence.com

Tel: +1 877 441 4866

Website: www.datamintelligence.com

[marketglobalresearchreport]

Global Viral Vector Vaccines Market Size, Share, Trends, Growth, Demand and Estimates to 2027

The recently Published Report titled Global Viral Vector Vaccines Market Size, Share, Trends, Growth, Demand and Estimates to 2027 by Axel Reports offers a comprehensive picture of the market from the global view point as well as a descriptive analysis with detailed segmentation, complete research and development history, latest news, offering a forecast and statistic in terms of revenue during the forecast period from 2021-2027. The report covers a comprehensive analysis of key segments, recent trends, competitive landscape, and key factors playing a substantial role in the market are detailed in the report. The report helps vendors and manufacturers to understand the change in the market dynamics over the years.

Get Sample Copy of this Report with the Latest Market Trend and COVID-19 Impact: https://axelreports.com/request-sample/55827

Global Market Segmentation by Top Key-Players: Advanced Bioscience Laboratories Creative Biogene Boehringer Ingelheim Sanofi Brammer Bio Pfizer GE Healthcare

NOTE: Consumer behaviour has changed within all sectors of the society amid the COVID-19 pandemic. Industries on the other hand will have to restructure their strategies in order to adjust with the changing market requirements. This report offers you an analysis of the COVID-19 impact on the Viral Vector Vaccines market and will help you in strategising your business as per the new industry norms.

Report offers: 1. Insights into the intact market structure, scope, profitability, and potential. 2. Precise assessment of market size, share, demand, and sales volume. 3. Authentic estimations for revenue generation and Viral Vector Vaccines Market development. 4. Thorough study of Viral Vector Vaccines Market companies including organizational and financial status. 5. Perception of crucial market segments including, forecast study. 6. Acumen of upcoming opportunities and potential threats and risks in the market.

Market segments by Types of, the report covers- Adenovirus Fowlpox Virus Attenuated Yellow Fever Vaccinia Virus Vectors Others Market segments by Applications of, the report covers- Hospitals Clinics Others

The report diversifies the global geographical expanse of the market into five prominent regions as:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

Key Elements Discussed In The Report: The report then discusses important dynamics on the business drivers that have a major impact on the performance are given in the report. The business drivers are important to the business operations and financial results of the industry. All the drivers are determined in the research study using market analysis. The report is comprehensive coverage of the existing and potential markets along with their assessment of their competitive position in the changing market scenario. It scrutinizes in-depth global market trends and outlook coupled with the factors driving the global Viral Vector Vaccines market, as well as those hindering it.

Get Up to 30% Discount on the first purchase of this report @ https://axelreports.com/request-discount/55827

Moreover, the report throws light on the pinpoint analysis of global Viral Vector Vaccines market dynamics. It also measures the sustainable trends and platforms which are the basic roots behind the market growth. With the help of SWOT and Porter’s five analysis, the market has been deeply analyzed. Consumer behavior is assessed with respect to current and upcoming trends. The report takes a detailed note of the major industrial events in past years. These events include several operational business decisions, innovations, mergers, collaborations, major investments, etc.

Customization of the Report: This report can be customized to meet the client’s requirements. Please connect with our sales team ( sales@axelreports.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +18488639402 to share your research requirements.

ABOUT Axel Reports:

Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact: Axel Reports Akansha G (Knowledge Partner) Office No- P 221 Pune, Maharashtra 411060 Phone: US +18488639402 Web: https://axelreports.com/

[researchcognizance]

Global Viral Vector Vaccines Market Expected to Witness Rapid Expansion by the End of 2027

The recent report on “Global Viral Vector Vaccines Market Report 2021 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2027” offered by Axel Reports, comprises a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the “Viral Vector Vaccines Market”.

An exhaustive competition analysis that covers insightful data on industry leaders is intended to help potential market entrants and existing players in competition with the right direction to arrive at their decisions. Market structure analysis discusses in detail Viral Vector Vaccines companies with their profiles, revenue shares in the market, comprehensive portfolio of their offerings, networking and distribution strategies, regional market footprints, and much more.

Download Sample PDF+ All Related Graphs & Charts (Including COVID19 Impact Analysis) @: https://axelreports.com/request-sample/55827

By Market Players: Advanced Bioscience Laboratories Creative Biogene Boehringer Ingelheim Sanofi Brammer Bio Pfizer GE Healthcare

By Type Adenovirus Fowlpox Virus Attenuated Yellow Fever Vaccinia Virus Vectors Others By Application Hospitals Clinics Others

(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)

Key Questions Covered in the Report :

What is the total market value of the Global Viral Vector Vaccines Market report?

What would be the forecast period in the market report?

What is the market value of the Global Viral Vector Vaccines Market in 2021?

What is the Key Industry Leader’s opinion for the Global Viral Vector Vaccines?

Which is the base year calculated in the Global Viral Vector Vaccines Market Report?

What are the key trends in the Global Viral Vector Vaccines Market Report?

What are the market values/growth % of emerging countries?

Which market holds the maximum market share of the Global Viral Vector Vaccines Market?

Some Point from Table of Content:

Market Overview: It includes six chapters, research scope, major manufacturers covered, market segments by type, Viral Vector Vaccines market segments by application, study objectives, and years considered.

Market Landscape: Here, the competition in the Worldwide Viral Vector Vaccines Market is analyzed, by price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Profiles of Manufacturers: Here, leading players of the global Viral Vector Vaccines market are studied based on sales area, key products, gross margin, revenue, price, and production.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Viral Vector Vaccines Market is deeply analysed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the global Viral Vector Vaccines Market.

Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://axelreports.com/enquiry-before-buying/55827

Note: This content doesn’t contain all the Information of the Report please fill the form (via link) and get all interesting information just one click in PDF with the latest update with chart and Table of Content. Any special requirements about this report, please let us know and we can provide custom report.

ABOUT US:

Axel Reports has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact: Axel Reports Akansha G (Knowledge Partner) Office No- B 201 Pune, Maharashtra 411060 Phone: US +18488639402 Web: https://axelreports.com/

sales@axelreports.com

[ken-research-market-research]

Global Adenovirus Vector Vaccine market- Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast 2021-2027: Ken Research

Global Adenovirus Vector Vaccine market- Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth and Forecast 2021-2027: Ken Research

The global Adenovirus Vector Vaccine market is expected to reach USD XX Million by 2027, with a CAGR of XX% from 2020 to 2027, based on HNY Research newly published report. The prime objective of this report “Global Adenovirus Vector Vaccine Industry Research Report 2021 Segmented by Major Market Players, Types, Applications and Countries Forecast to 2027” is to provide the insights on the post…

[leonfrancisblog]

Viral Vector and Vaccine Market is Rising exponentially at a Healthy CAGR of 14.50% During the Anticipated Period of 2020 to 2027| Novasep, MerckKGaA, Cobra Biologics Ltd., uniQure N.V., Waisman, Creative-Biogene

Viral Vector and Vaccine Market size is expected grow at a compound annual growth rate of 14.50% in the forecast period of 2020 to 2027 due to the growing prevalence of disease such as cancer, cardiac diseases, HIV and hemophilia which has raised the need for the development of therapies using viral vector and is primarily driving the market growth rate. Beside this, the presence of untapped medical sector in some regions and rising government initiatives for R&D sector of healthcare sector will produce lucrative opportunities for the growth of the viral vector and vaccine market.

High transfection efficiency, effective gene delivery and stable gene expression have made viral vectors preferred choice for gene transfer and it is evident by increasing clinical trials on viral vector medicated gene therapy. Increasing prevalence of disease such as cardiac diseases, cancer, HIV, Hemophilia has raised need for the development of therapies using viral vector whereas advancement in technology to manufacture viral vector is the key factor driving market growth. Moreover rising adoption of viral vectors by biopharmaceutical industries and increasing cost effective treatments are factor propelling market demand whereas lack of skilled professionals and high cost are factors restraining market growth. However untapped medical sector in some regions and increasing government initiatives for R&D sector of healthcare sector will produce lucrative opportunities in coming years.

Global Viral Vector & Vaccine Market By Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Workflow Upstream Processing, Downstream Processing, Application (Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology), Disease (Cancer, Genetic Disorders, Infectious Diseases, Others), End Use (Pharmaceutical and Biopharmaceutical Companies, Research Institutes), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2027 This viral vector & vaccine market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on viral vector & vaccine market contact us for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Get Sample PDF of Viral Vector and Vaccine Market Report (including COVID19 Impact Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-viral-vector-and-vaccine-market

Viral Vector and Vaccine Market Scope:

Viral vector and vaccine market is segmented on the basis of countries into the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

All country based analysis of viral vector and vaccine market is further analyzed based on maximum granularity into further segmentation. Based on type, the viral vector & vaccine market is segmented into adenovirus, retrovirus, plasmid DNA, AAV, lentivirus, and others. Based on workflow, the viral vector and vaccine market is segmented into upstream processing, downstream processing. Based on application, the viral vector & vaccine market is segmented into antisense & RNAi, gene therapy, cell therapy, and vaccinology. On the basis of disease, viral vector and vaccine market is segmented into cancer, genetic disorders, infectious diseases, and others. Viral vector and vaccine market has also been segmented based on end use into pharmaceutical and biopharmaceutical companies, and research institutes.

Viral vectors are one of the promising tools that are used for gene therapy and vaccines. Viral vector-based vaccines can improve immunogenicity without an adjuvant and encourage a robust cytotoxic T lymphocyte response to eradicate virus infected cells.

Key Market Competitors Covered in the report:

Novasep, MerckKGaA, Cobra Biologics Ltd., uniQure N.V., Waisman, Creative-Biogene, Aldevron, Addgene, Oxford Biomedica, Thermo Fisher Scientific Inc, Cell Therapy Catapult Limited Eurogentec, Fujifilm, Spark Therapeutics Inc. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Key Pointers Covered in the Viral Vector Market Size:

Market New Sales Volumes

Market Replacement Sales Volumes

Market Installed Base

Market By Brands

Market Procedure Volumes

Market Product Price Analysis

Market Healthcare Outcomes

Market Cost of Care Analysis

Market Regulatory Framework and Changes

Prices and Reimbursement Analysis

Market Shares in Different Regions

Recent Developments for Market Competitors

Market Upcoming Applications

Market Innovators Study

MAJOR TOC OF THE REPORT:

Chapter One: Viral Vector and Vaccine Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Viral Vector and Vaccine Market Competition, by Players

Chapter Four: Viral Vector and Vaccine Market Size by Regions

Chapter Five: Viral Vector and Vaccine Market Revenue by Countries

Chapter Six: Viral Vector and Vaccine Market Revenue by Type

Chapter Seven: Viral Vector and Vaccine Market Revenue by Application

Chapter Eight: Viral Vector and Vaccine Market Revenue by Industries

Chapter Nine: Viral Vector and Vaccine Market Revenue by Deployment Model

Chapter Ten: Viral Vector and Vaccine Market Revenue by End User

Get Detail TOC@ https://www.databridgemarketresearch.com/toc/?dbmr=global-viral-vector-and-vaccine-market  

Key Report Highlights:

Comprehensive pricing analysis based on different product types and regional segments

Market size data in terms of revenue and sales volume

Deep insights about regulatory and investment scenarios of the global Information Rights Management Market

Analysis of market effect factors and their impact on the forecast and outlook of the global Information Rights Management Market

The detailed assessment of the vendor landscape and leading companies to help understand the level of competition in the global Information Rights Management Market

A roadmap of growth opportunities available in the Global Information Rights Management Market with the identification of key factors

The exhaustive analysis of various trends of the Global Information Rights Management Market to help identify market developments

Key Questions Answered in Report:

What is the key to the Information Rights Management Market?

What will the Information Rights Management Market Demand and what will be Growth?

What are the latest opportunities for Information Rights Management Market in the future?

What are the strengths of the key players?

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-viral-vector-and-vaccine-market  

Browse Related Reports@

Pediatric Vaccine Market 

Human Rotavirus Vaccine Market

Veterinary Clostridium Vaccine Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

[cmfelatestarticle]

Cancer Gene Therapy Market is predicted to reach USD 16,494.66 million by 2030

Cancer Gene Therapy Market is predicted to reach USD 16,494.66 million by 2030The Global Cancer Gene Therapy Market held USD 558.24 million in 2018 and is predicted to reach USD 16,494.66 million by 2030 with a CAGR of 32.6% from 2019-2030

Read Report Overview @

https://www.nextmsc.com/report/cancer-gene-therapy-market

Cancer gene therapy is a technique of healing distribution of genetic material into a patient's cells as a drug to treat disease and compensate for abnormal genes or to make a beneficial protein. The cancer cells can modify themselves in numerous genetic factors that make them further divide into very often and form a tumor.

During the treatment of cancer, the genes are replaced to fight against cancer-causing tumor cells. Gene therapy is an effective treatment for chronic diseases as they cause least side effects with maximum efficacy. The innovation in the gene therapy with better success rate and increasing prevalence of cancer worldwide is generating new opportunity for cancer gene therapy market.

The cancer gene therapy market size is growing owing to factors including increased prevalence of cancer, the growing popularity of DNA vaccines. Furthermore, increasing funding for R&D activities for cancer gene therapy majorly driven the cancer gene therapy market. Further, ethical acceptance of gene therapy for treatment of diseases, and favorable government regulations growing has further supplemented the market growth. However, the high cost of gene therapy treatment and unwanted immune responses is hampering the growth of the cancer gene therapy market. The rapid technological advancements and untapped markets in developing economies will open new opportunities for cancer gene therapy market share in the future.

The cancer gene therapy market is segmented on the basis of therapy, end-user, and geography. On the basis of therapy, the cancer gene therapy market is classified into gene induced immunotherapy, gene transfer, and oncolytic virotherapy. The gene induced immunotherapy is further sub-segmented into the delivery of cytokines gene and delivery of tumor antigen gene. The gene transfer is further sub-segmented into naked/plasmid vectors, sonoportion, magnetofection, electroporation, and gene gun. The oncolytic virotherapy segment is further sub-segmented into adenovirus, lentivirus, vaccinia virus, herpes simplex virus, alpha virus, retro virus, adeno associated virus, simian virus, and others. On the basis of application, the market is divided into hospitals, diagnostics centers, and research institutes. Geographic breakdown and analysis of each of the aforesaid segments include regions comprising North America, Europe, Asia-Pacific, and LAMEA.

North America denotes a higher adoption of the cancer gene therapy and is anticipated to hold the highest market share during the forecast period. This is attributable to the factors including enhanced developments in healthcare, a large number of aging population, technological advancement, and high consumer awareness.

It is expected that the emerging economies, specifically in the Asia-Pacific region would witness increasing market size owing to improvement in a healthcare facility, increasing government initiatives, and increasing the affordability for advanced treatment due to increasing disposable income.

Request to view Sample Report:

https://www.nextmsc.com/Cancer-Gene-Therapy-Market/request-sample

Comprehensive competitive analysis and profiles of the major market players such as Bluebird bio, Inc., Merck, Adaptimmune, GlaxoSmithKline, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Celgene, Shanghai Sunway Biotech, OncoGenex Pharmaceuticals, and among others are provided in the cancer gene therapy market report.

[captainvileshmodiworld-blog]

Global Viral Vector Vaccines Market 2019 | Manufacturers In-Depth Analysis Report to 2024

The latest trending report Global Viral Vector Vaccines Market 2019-2024 added by DecisionDatabases.com

Viral vector vaccines combine many of the positive qualities of DNA vaccines with those of live attenuated vaccines.

The worldwide market for Viral Vector Vaccines is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019.

This report focuses on the Viral Vector Vaccines in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/40542-viral-vector-vaccines-industry-analysis-report

Market Segment by Manufacturers, this report covers

·          Advanced Bioscience Laboratories

·          Boehringer Ingelheim

·          Brammer Bio

·          Creative Biogene

·          GE Healthcare

·          Pfizer

·          Sanofi

Market Segment by Regions, regional analysis covers

·          North America (United States, Canada and Mexico)

·          Europe (Germany, France, UK, Russia and Italy)

·          Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

·          South America (Brazil, Argentina, Colombia etc.)

·          Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

·          Adenovirus

·          Fowlpox Virus

·          Attenuated Yellow Fever

·          Vaccinia Virus Vectors

·          Others

Market Segment by Applications, can be divided into

·          Hospitals

·          Clinics

·          Others

Download Free Sample Report of Global Viral Vector Vaccines Market @ https://www.decisiondatabases.com/contact/download-sample-40542

The content of the study subjects, includes a total of 15 chapters: Chapter 1, to describe Viral Vector Vaccines product scope, market overview, market opportunities, market driving force and market risks. Chapter 2, to profile the top manufacturers of Viral Vector Vaccines, with price, sales, revenue and global market share of Viral Vector Vaccines in 2017 and 2018. Chapter 3, the Viral Vector Vaccines competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4, the Viral Vector Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019. Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019. Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019. Chapter 12, Viral Vector Vaccines market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024. Chapter 13, 14 and 15, to describe Viral Vector Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Purchase the complete Global Viral Vector Vaccines Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-40542

All Vaccines Related Reports by DecisionDatabases.com @ https://goo.gl/Q2GmDt

About-Us: DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.

Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise and meaningful data at a lightning speed.

For more details: DecisionDatabases.com E-Mail: sales@decisiondatabases.com Phone: +91 9028057900 Web: https://www.decisiondatabases.com/

[metiresearchinfo]

Pharmaceutical Contract Development and Manufacturing Market By Service [Pharmaceutical Manufacturing Services (API, FDF), Drug Development Services, Biologics Development], End User [Big & Generic Pharmaceutical Companies] – Global Forecast to 2027

The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 6.5% from 2020 to 2027 to reach $134.23 billion by 2027. The complex structure for manufacturing pharmaceuticals, increasing investments in pharmaceutical R&D, growing outsourcing of clinical trials, and the outbreak of the COVID-19 pandemic are some of the major drivers for the growth of this market. In addition, the rising demand for generic medicines & biologics, growing demand for cell & gene therapies, and increasing pharmaceutical outsourcing support the growth of this market. However, service quality & IPR issues, lack of skilled professionals, and introduction of serialization are the factors expected to hinder the growth of the pharmaceutical contract development and manufacturing market during the forecast period.  

COVID-19 Impact on the Pharmaceutical Contract Development and Manufacturing Market      

The recent outbreak of COVID-19 has impacted the healthcare market. The pharmaceutical contract development and manufacturing industry has experienced a positive impact due to this pandemic. The outbreak has catalyzed the demand for pharmaceuticals and has stirred the development of corona-related vaccines, antiviral vaccines, antibody therapy, and various pharmaceutical products. This has urged pharmaceutical organizations to hire contract development and manufacturing organizations for pharmaceutical drug development & manufacturing to sustain their business.

The demand for both high quality and high volume CGMP drug substance and drug product manufacturing services has soared, particularly for CDMOs able to support a wide range of COVID vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

Most pharmaceutical companies, CROs, and research institutes are working together to translate research into effective pharmaceutical products. For instance, in August 2020, Catalent Inc. (U.S.) signed an agreement with AstraZeneca PLC (U.K.) to expand manufacturing support for the University of Oxford’s adenovirus vector-based COVID-19 vaccine AZD1222. In September 2020, Thermo Fisher Scientific Inc. (U.S.) partnered with Inovio Pharmaceuticals, Inc. (U.S.) to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800 and to enhance the commercial production of INO-4800.

                                                              Click here to: Get Free Sample Pages of this Report

Increasing investments in the pharmaceutical R&D support the market growth

The pharmaceutical industry is largely driven by scientific discovery and development, in conjunction with toxicological and clinical experience. Also, healthcare R&D activities have significantly increased with rising funding from various government organizations. This funding is mainly driven by rising health care concerns, complexities in clinical trials, and drug failure in early-phase studies.

Governments in developed and developing nations are offering to fund the propagation of biotechnology and biopharmaceutical research. For instance, the Indian government launched 'Pharma Vision 2020' to increase the production capacities of biopharmaceuticals by reducing the approval time for new facilities. Also, the government decided in favor of 100% foreign direct investment in the pharmaceutical industry, which is expected to increase investments in R&D activities. Similarly, in the U.S., the National Institute of Health (NIH) collaborated with 11 biopharmaceutical companies to launch the Partnership for Accelerating Cancer Therapies (PACT) to develop immunotherapy for cancers. The program involved a total investment of USD 215 million.

Further, pharmaceutical companies have also increased their spending on R&D. The extent of pharmaceutical R&D spending serves as an important metric to show a company’s commitment to finding new drugs. At present, the global pharmaceutical industry has the second-highest R&D intensity, i.e. expenditure as a share of any sector's sales measures. Thus, the increasing investments from the government for pharmaceutical R&D is likely to boost outsourcing, thereby accelerating pharmaceutical contract development & manufacturing market growth.

Growing consolidation in the market, an ongoing trend

Due to growing pressure on leading pharmaceutical players, complex drug development process, growing number of patents expiring, increasing R&D costs, and the increasing prevalence of chronic diseases are some of the factors making outsourcing essential.

CDMOs offer the convenience of time and cost due to the inherent nature of dealing with a single entity. The relationship also creates opportunities for the pharmaceutical CDMOs to sell more services to the same customer and locking in products at earlier stages of their life cycles.

Due to the growing pressure on the industry’s leading players to follow stringent regulatory timelines and lack of human clinical trial data, pharmaceutical giants are entering into collaborations, partnerships, and agreements to jointly broaden their services offered across all drug development & pharmaceutical manufacturing processes:

In June 2020, Catalent Inc. (U.S.) collaborated with Moderna, Inc. (U.S.) for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273).

In April 2020, ICON plc (Ireland) agreed with Pfizer Inc. (U.S.) to supply drug and device development and commercialization services.

                                              Click here to: Get a Free Request Sample Copy of this report

Key Findings in the Pharmaceutical Contract Development and Manufacturing Market Study:

Pharmaceutical manufacturing services generated a large proportion of revenue compared to other services

The large share of this segment is mainly attributed to the use of advanced technologies & manufacturing skills, the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs.

Pharmaceutical API contract manufacturing services are estimated to account for the largest share of the pharmaceutical contract manufacturing services market in 2020

The need for the reduction in the cost of production of APIs, growing number of initiatives undertaken by pharmaceutical companies, increasing investments in API manufacturing services, and growing need to reduce the time required for the drug development process are expected to drive the growth of the pharmaceutical API contract manufacturing services segment.

In 2020, the big pharmaceutical companies segment to dominate pharmaceutical contract development and manufacturing market

The major share of this segment is primarily attributed to the growing prevalence of various infectious diseases, growing need for state-of-the-art processes & production technologies, and the rising cost of clinical trials and early development studies.

Asia-Pacific: Fastest growing regional market

In 2020, North America is estimated to command the largest share of the pharmaceutical contract development and manufacturing market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. However, Asia-Pacific will be the fastest-growing regional market due to the growing manufacturing sector, favorable government regulations, increasing emphasis on off-patent drugs, and highly skilled workforce in the region. In addition, the increase in outsourcing activities in countries like India and China due to lower costs and availability of qualified healthcare professionals are the other key factors propelling the growth of the Asia-Pacific pharmaceutical contract development and manufacturing market.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past four years. The key players profiled in the pharmaceutical contract development and manufacturing market report are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.),  PPD Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma-Fertigung GmbH & Co. KG  (Germany), AbbVie Inc. (U.S.), Synoes Health, Inc. (U.S.), Piramal Enterprises Limited (India), Almac Group (U.K.), Albany Molecular Research Inc. (U.S.), Fareva Holding SA (France), and Jubilant Life Sciences Limited (India).

Scope of the Report:

Pharmaceutical Contract Development and Manufacturing Market, by Service

Pharmaceutical Manufacturing Services

Drug Development Services

Biologics Manufacturing Services

Pharmaceutical API Manufacturing Services

Pharmaceutical FDF Manufacturing Services

Parenteral/Injectable Manufacturing Services

Tablet Manufacturing Services

Capsule Manufacturing Services

Oral Liquid Manufacturing Services

Other Formulations Manufacturing Services

Biologics API Manufacturing Services

Biologics API Manufacturing Services

Pharmaceutical Contract Development and Manufacturing Market, by End User

Big Pharmaceutical Companies

Small and Med-Size Pharmaceutical Companies

Generic Pharmaceutical Companies

Pharmaceutical Contract Development and Manufacturing Market, by Geography

North America

Europe

Asia-Pacific (APAC)

Latin America

Middle East & Africa

U.S.

Canada

Germany

U.K.

France

Italy

Spain

Rest of Europe (RoE)

China

Japan

India

Rest of APAC (RoAPAC)

[aditi-us]

Global Gene Therapy Market is Expected to Thrive at a CAGR of 33.3% Forecast period 2017-2023

A Comprehensive research study conducted by KD Market Insights on "Gene Therapy Market by Vector Type (Viral Vector and Non-viral Vector), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, and Others), and Applications (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Disease, and Other Diseases) - Global Opportunity Analysis and Industry Forecast, 2017-2023" report offers extensive and highly detailed historical, current and future market trends in the global and regional/market. The Gene Therapy Market report includes market size, growth drivers, barriers, opportunities, trends and other information which helps to find new opportunities in this market for the growth of the business through new technologies and developments. The Global Gene Therapy Market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patient’s cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy. Request for Sample @ https://www.kdmarketinsights.com/sample/3544 The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market. The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. KEY MARKET BENEFITS - This report offers a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities. - The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry. - In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning. - The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market. KEY MARKET SEGMENTS By Vector Type - Viral vector - - Retroviruses - - Lentiviruses - - Adenoviruses - - Adeno Associated Virus - - Herpes Simplex Virus - - Poxvirus - - Vaccinia Virus - - Others - Non-viral vector - - Naked/Plasmid Vectors - - Gene Gun - - Electroporation - - Lipofection - - Others By Gene Type - Antigen - Cytokine - Tumor Suppressor - Suicide - Deficiency - Growth factors - Receptors - Others By Application - Oncological Disorders - Rare Diseases - Cardiovascular Diseases - Neurological Disorders - Infectious disease - Other Diseases By Region - North America - - U.S. - - Canada - - Mexico - Europe - - Germany - - UK - - France - - Spain - - Italy - - Rest of Europe - Asia-Pacific - - Japan - - China - - India - - South Korea - - Rest of Asia-Pacific - LAMEA - - Brazil - - Republic of South Africa - - Rest of LAMEA KEY PLAYERS PROFILED - Novartis - Kite Pharma, Inc. - GlaxoSmithKline PLC - Spark Therapeutics Inc. - Bluebird bio Inc. - Genethon - Transgene SA - Applied Genetic Technologies Corporation - Oxford BioMedica - NewLink Genetics Corp. Browse Full Report with TOC @ https://www.kdmarketinsights.com/product/gene-therapy-market-amr Table of Contents: CHAPTER 1 INTRODUCTION 1.1. Report description 1.2. Key benefits 1.3. Key market segments 1.4. Research methodology 1.4.1. Secondary research 1.4.2. Primary research 1.4.3. Analyst tools and models CHAPTER 2: EXECUTIVE SUMMARY 2.1. CXO perspective CHAPTER 3: MARKET OVERVIEW 3.1. Market definition and scope 3.2. Key findings 3.2.1. Top investment pockets 3.2.2. Top winning strategies 3.2.2.1. Top winning strategies, by year, 2015-2017* 3.2.2.2. Top winning strategies, by development, 2015-2017* (%) 3.2.2.3. Top winning strategies, by company, 2015-2017* 3.3. Top player positioning, 2016 3.4. Porters five forces analysis 3.5. Market dynamics 3.5.1. Drivers 3.5.1.1. High investment for R&D activities pertaining to gene therapy 3.5.1.2. Increase in prevalence of cancer 3.5.1.3. Growth in awareness regarding gene therapy 3.5.2. Restraints 3.5.2.1. High cost associated with gene therapies 3.5.2.2. Unwanted immune responses 3.5.3. Opportunity 3.5.3.1. Untapped potential for emerging markets CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE 4.1. Overview 4.1.1. Market size and forecast 4.2. Viral vectors 4.2.1. Key market trends 4.2.2. Key growth factors and opportunities 4.2.3. Market size and forecast 4.2.4. Market Analysis by country 4.2.5. Adenovirus 4.2.6. Lentivirus 4.2.7. Retrovirus 4.2.8. Adeno-associated virus 4.2.9. Herpes simplex virus 4.2.10. Poxvirus 4.2.11. Vaccinia virus 4.2.12. Others 4.3. Nonviral techniques 4.3.1. Key market trends 4.3.2. Key growth factors and opportunities 4.3.3. Market size and forecast 4.3.4. Market Analysis by country 4.3.5. Naked plasmid vector 4.3.6. Gene gun 4.3.7. Electroporation 4.3.8. Lipofection 4.3.9. Others CHAPTER 5: GENE THERAPY MARKET, BY GENE TYPE 5.1. Overview 5.1.1. Market size and forecast 5.2. Antigen 5.2.1. Market size and forecast 5.2.2. Market size and forecast by country 5.3. Cytokine 5.3.1. Market size and forecast 5.3.2. Market Analysis, by country 5.4. Tumor suppressor 5.4.1. Market size and forecast 5.4.2. Market Analysis, by country 5.5. Suicide 5.5.1. Market size and forecast 5.5.2. Market Analysis, by country Continue… Check for Discount @ https://www.kdmarketinsights.com/discount/3544 About Us: KD Market Insights offers a comprehensive database of syndicated research studies, customized reports, and consulting services. These reports are created to help in making smart, instant and crucial decisions based on extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Our dedicated in-house team ensures the reports satisfy the requirement of the client. We aim at providing value service to our clients. Our reports are backed by extensive industry coverage and is made sure to give importance to the specific needs of our clients. The main idea is to enable our clients to make an informed decision, by keeping them and ourselves up to date with the latest trends in the market. Contact Us: KD Market Insights 150 State Street, Albany, New York, USA 12207 +1 (518) 300-1215 Email: sales@kdmarketinsights.com Website: www.kdmarketinsights.com  

[sagarj-things-blog]

Polyinosinic Acid Market By Manufacturers, Type and Applications, Status and Forecast, 2016-2024

Global Polyinosinic Acid Market: Overview

Polyinosinic acid used as a model RNA, is composed of a polynucleotide chain. It consists entirely of inosinic acid residues. Polyinosinic acid is made from polycytidylic acid. It is a homopolymer of inosine used with polycytidylic acid to form a double stranded homopolymer. This acts as a major effector of the immune response against viral pathogens. Polyinosinic acid is primarily used in the form of sodium salt to simulate viral infections.

Browse Market Research Report: http://www.transparencymarketresearch.com/polyinosinic-acid-market.html

Polyinosinic acid (abbreviated as Poly I:C) along with polycytidylic acid acts as an immunostimulant. It is known to interact with toll-like receptor 3, which is expressed in the membrane of B-cells, macrophages, and dendritic cells. Polyinosinic acid enhances delivery of adenovirus vectors. It is used primarily in pharmaceuticals, health care, and medical sectors. Polyinosinic acid is employed as a potent adjuvant in the medical sector to enhance the specific anti-tumor immune responses against a peptide-based vaccine. Growth in pharmaceutical and health care sectors is expected to boost the demand for polyinosinic acid in the next few years. Polyinosinic acid is anticipated to penetrate the market rapidly due to the various research and development activities conducted by several companies and medical organizations. It is not available widely since it is medical product; however, demand for polyinosinic acid is high due to its anti-tumor immune responses. Polyinosinic acid requires ionic strength to maintain the double strand structure. In order to prevent denaturation, polyinosinic acid is reconstituted in solutions with physiological salt concentrations. Furthermore, it may require heating and cooling to achieve re-annealing.

Asia Pacific held the major share of the polyinosinic acid market in 2015, led by the high growth of pharmaceutical and medical sectors. Demand for polyinosinic acid is also high in Europe and North America. The U.S., Germany, China, India, and Japan accounted for key share of the polyinosinic market in 2015. Polyinosinic acid is highly produced and consumed in these countries due to the increase in population, high standard of living, rise in number of diseases among the people, and expansion in pharmaceutical and medical sectors. Middle East & Africa constituted smaller share of the polyinosinic market in 2015; however, demand for polyinosinic acid is anticipated to rise at a rapid pace in the region in the next few years. Optimization of physicochemical properties of polyinosinic acid has led to generation of derivatives that have increased stability in body fluids (such as polyICLC), or reduced toxicity through reduced stability in body fluids. This is estimated to boost the polyinosinic acid market during the forecast period.

Get accurate market forecast and analysis on the Polyinosinic Acid market. Request a sample to stay abreast on the key trends impacting this market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22208

Key manufacturers of polyinosinic acid across the globe include Biotain Pharma Co. Ltd., N&R Bio Industries Inc., Beijing Isomersyn Technology Co. Ltd., Hubei XinyuanShun Chemical Co. Ltd., and Hangzhou Dingyan Chem. Co. Ltd.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/